Abstract
Numerous studies have shown that weight loss is associated with an increase in mortality [1] [4]. Treating weight loss in the elderly can ameliorate many medical conditions. For example, rehabilitation time following post-hip fractures has been shown to decrease with nutritional supplementation [5]. In hospitalised geriatric patients, nutritional supplementation resulted in improvement in serum protein, nutritional status, and decreased mortality [6]. In a subset of geriatric inpatients, low serum albumin with weight loss predicts those patients at highest risk for dying during the subsequent 2 years [7]. Riquelme and Torres et al. [8] carried out a multivariate analysis of risk and prognostic factors in community-acquired pneumonia in the elderly and found that age by itself was not a significant factor related to prognosis. Among the significant risk factors, only nutritional status is amenable to medical intervention. In the cachectic elderly, medical, cognitive, and psychiatric disorders may diminish self-sufficiency in activities of daily living (ADL), thus reducing the quality of life and increasing the frequency of secondary procedures, hospitalisations, and need for skilled care [2, 9].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sullivan DH, Walls RC (1994) Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients. J Am Geriatr Soc 42:471–477
Sullivan DH (1995) Impact of nutritional status on health outcomes of nursing home residents. J Am Geriatr Soc 43:195–196
Sullivan DH, Walls RC, Bopp MM (1995) Proteinenergy undernutrition and the risk of mortality within one year of hospital discharge: a follow-up study. J Am Geriatr Soc 43:507–512
Sullivan DH (1995) The role of nutrition in increased morbidity and mortality. Clin Geriatr Med 11:661–674
Bastow MD, Rawlings J, Allison SP (1983) Benefits of supplementary tube feeding after fractured neck of femur: a randomized controlled trial. Br Med J 287:1589–1592
Woo J, Ho SC, Mak YT et al (1994) Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. Age Ageing 23:40–48
McMurtry C, Rosenthal A (1995) Predictors of 2-year mortality among older male veterans on a geriatric rehabilitation unit. J Am Geriatr Soc 43:1123–1126
Riquelme R, Torres A, El-Ebiary M et al (1996) Community-acquired pneumonia in the elderly. Am J Respir Crit Care Med 154:1450–1455
Sullivan D, Walls R (1994) Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients. J Am Geriatr Soc 42:471–477
Morley J, Kraenzle D (1994) Causes of weight loss in a community nursing home. J Am Geriatr Soc 42:583–585
Robbins LJ (1989) Evaluation of weight loss in the elderly. Geriatrics 44:31–34,37
Kayser-Jones J (2001) Starved for attention. Reflect Nurs Leadersh 27:10–14,45
Rolls BJ, Dimeo KA, Shide DJ (1995) Age-related impairments in the regulation of food intake. Am J Clin Nutr 62:923–931
Moriguti JC, Das SK, Saltzman E et al (2000) Effects of a 6-week hypocaloric diet on changes in body composition, hunger, and subsequent weight regain in healthy young and older adults. J Gerontol A Biol Sci Med Sci 55:B580–B587
Roberts SB, Fuss P, Heyman MB et al (1994) Control of food intake in older men. JAMA 272:1601–1606
Roberts SB (2000) Regulation of energy intake in relation to metabolic state and nutritional status. Eur J Clin Nutr 54(Suppl 3):S64–S69
McCrory MA, Fuss PJ, McCallum JE et al (1999) Dietary variety within food groups: association with energy intake and body fatness in men and women. Am J Clin Nutr 69:440–447
Schiffman SS (1997) Taste and smell losses in normal aging and disease. JAMA 278:1357–1362
White HK, McConnell ES, Bales CW, Kuchibhatla M (2004) A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer’s disease subjects. J Am Med Dir Assoc 5:89–97
Simmons, SF, Osterweil D, Schnelle JF (2001) Improving food intake in nursing home residents with feeding assistance: a staffing analysis. J Gerontol A Biol Sci Med Sci 56:M790–M794
Murphy DJ, Santilli S (1998) Elderly patients’ preferences for long-term life support. Arch Fam Med 7:484–488
Abitbol V, Selinger-Leneman H, Gallais Y et al (2002) Percutaneous endoscopie gastrostomy in elderly patients. A prospective study in a geriatric hospital. Gastroenterol Clin Biol 26:448–453
Mitchell, SL, Tetroe JM (2000) Survival after percutaneous endoscopie gastrostomy placement in older persons. J Gerontol A Biol Sci Med Sci 55:M735–M739
Gomez Ramos, MJ, Saturno Hernandez PJ (2002) Parenteral nutrition in a general hospital: quality criteria and factors associated with compliance. Med Clin (Barc) 119:686–689
Shintani S, Fumimura Y, Shiigai T et al (2001) Feeding methods for long-term bedridden patients with dysphagia under home health care—percutaneous endoscopic gastrostomy (PEG) and intravenous hyperalimentation (IVH). Gan To Kagaku Ryoho 28(Suppl l):61–64
Ling PR, Khaodhiar L, Bistrian BR et al (2001) Inflammatory mediators in patients receiving longterm home parenteral nutrition. Dig Dis Sci 46:2484–2489
McNamara M, Alexander H, Norton J (1992) Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enterai Nutr 16(Suppl 6):S50–S55
Tisdale M (1997) Biology of cachexia. J Natl Cancer Inst 89:1763–1773
Tisdale M, McDevitt TM, Todorov PT et al (1996) Catabolic factors in cancer cachexia. In vivo 10:131–136
Tisdale MJ (2003) The ‘cancer cachectic factor’. Support Care Cancer 11:73–78
Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871
Tisdale MJ (2001) Cancer anorexia and cachexia. Nutrition 17:438–442
Kotier DP, Grunfeld C (1995) Pathophysiology and treatment of the AIDS wasting syndrome. AIDS Clin Rev 96:229–275
Tokuda Y, Koketsu H (2002) High mortality in hospitalized elderly patients with feeding tube placement. Intern Med 41:613–616
Yeh SS, Hafner A, Schuster MW et al (2003) Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 51:890–891
Yeh SS, Schuster MW (1999) Geriatric cachexia: the role of cytokines. Am J Clin Nutr 70:183–197
Yeh SS, Schuster MW (2000) Reply to JL Caddell. Am J Clin Nutr 71:852–853
Yeh SS, Wu SY, Levine DM et al (2001) The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 56:M48–M54
Morgan L (1985) Megestrol acetate versus tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 12:43–47
Muss HB, Case LD, Capizzi RL et al (1990) High-versus standard dose megestrol acetate in woman with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797–1805
Tchekmedyian NS, Zahyna D, Halpert C, Heber D (1992) Clinical aspects of nutrition in advanced cancer. Oncology 49(Suppl 2):3–7
Tchekmedyian NS, Hickman M, Siau J et al (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268–1274
Tchekmedyian NS, Tait N, Moody M, Aisner J (1987) High-dose megestrol acetate. A possible treatment for cachexia. JAMA 257:1195–1198
Pascual Lopez A, Roquei Figuls M, Urrutia Cuchi G et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 27:360–369
Von Roenn JH, Armstrong D, Kotier DP et al (1994) Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 121:393–399
Von Roenn JH (1994) Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncology 51:19–24
Von Roenn JH, Murphy RL, Weber KM et al (1988) Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 10:840–841
Yeh SS, Wu SY, Lee TP et al (2000) Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a doubleblind, placebo-controlled study. J Am Geriatr Soc 48:485–492
Simmons SF, Walker KA, Osterweil D (2004) The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study. J Am Med Dir Assoc 5:24–30
Morley JE (2002) Orexigenic and anabolic agents. Clin Geriatr Med 18:853–866
Karcic E, Philpot C, Morley JE (2002) Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging 6:191–200
Lambert CP, Sullivan DH, Freeling SA et al (2002) Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab 87:2100–2106
Hamburger AW, Parnes H, Gordon GB et al (1988) Megestrol acetate induced differentiation of 3T3-L1 adipocytes in vitro. Semin Oncol 15:76–78
Reitmeier M, Hartenstein R (1990) Megestrol acetate and determination of body composition by bioelectrical impedance analysis in cancer cachexia. Proc Am Soc Clin Oncol 9:325 (abs)
Beck S, Tisdale M (1990) Effect of megestrol acetate on weight loss induced by tumor necrosis factor alpha and a cachexia-inducing tumor (MAC16) in NMRI mice. Br J Cancer 62:420–424
Lapp CA, Thomas ME, Lewis JB (1995) Modulation by progesterone of interleukin-6 production by gingival fibroblasts. J Periodontol 66:279–284
Mantovani G, Macciò A, Lai P et al (1998) Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 9:99–106
Mantovani G, Macciò A, Lai P et al (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25(Suppl 6):45–52
Mantovani G, Macciò A, Esu S et al (1997) Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33:602–607
Mantovani G (1997) Serum levels of cytokines and weightloss/anorexia in cancer patients. Support Care Cancer 5:422–423
Yeh SS, Wu SS, Levine DM et al (2000) Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite, and in geriatric patients. J Nutr Health Aging 4:246–251
Jatoi A, Yamashita J, Sloan JA et al (2002) Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 10:71–75
McCarthy HD, Crowder RE, Dryden S, Williams G (1994) Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 265:99–102
Costa AM, Spence KT, Plata-Salaman CR, FfrenchMullen JM (1995) Residual Ca2+ channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurones. J Physiol 487:291–303
Meacham LR, Mazewski C, Krawiecki N (2003) Mechanism of transient adrenal insufficiency with megestrol acetate treatment of cachexia in children with cancer. J Pediatr Hematol Oncol 25:414–417
McKone EF, Tonelli MR, Aitken ML (2002) Adrenal insufficiency and testicular failure secondary to megestrol acetate therapy in a patient with cystic fibrosis. Pediatr Pulmonol 34:381–383
Pimentel G, Santos E, Arastu M, Cowan JA (1996) Hyperglycemia in an AIDS patient taking megestrol. Hosp Pract (Off Ed) 31:27–28
Hervas R, Cepeda C, Pulido F (2004) Cushing syndrome secondary to megestrol acetate in a patient with AIDS. Med Clin (Barc) 122:638–639
Kropsky B, Shi Y, Cherniack EP (2003) Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 4:255–256
Thomas DR (2004) Incidence of venous thromboembolism in megestrol acetate users. J Am Med Dir Assoc 5:65–66; author reply 66–67
Bennett RG (2003) Megestrol complications. Chest 123:309–310; author reply 310
Naing KK, Dewar JA, Leese GP ( 1999) Megestrol acetate therapy and secondary adrenal suppression. Cancer 86:1044–1049
Mann M, Koller E, Murgo A et al ( 1997) Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 157:1651–1656
Gonzalez Del Valle L, Herrero Ambrosio A, Martinez Hernandez P et al (1996) Hyperglycemia induced by megestrol acetate in a patient with AIDS. Ann Pharmacother 30:1113–1114
Loprinzi CL, Fonseca R, Jensen MD ( 1996) Megestrol acetate-induced adrenal suppression. J Clin Oncol 14:689
Gorter RW (1999) Cancer cachexia and cannabinoids. Forsch Komplementarmed 6(Suppl 3):21–22
Gorter R (1998) Cannabis and cannabidiol: interview with Robert Gorter, MD. Interview by Fred Gardner. AIDS Treat News 305:4–6
Volicer L, Stelly M, Morris J et al (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 12:913–919
Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567–573
Beal JE, Olson R, Laubenstein L et al (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89–97
Struwe M, Kaempfer SH, Geiger CJ et al (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827–831
Batterham MJ, Garsia R (2001) A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl 24:232–240
Lyden E, Cvetkovska E, Westin T et al (1995) Effects of nandrolone propionate on experimental tumor growth and cancer cachexia. Metabolism 44:445–451
Gruzdev BM, Ivannikov EV, Gorbacheva ES (1999) Anabolic therapy in patients with HIV infections. Ter Arkh 71:35–37
Gold J, High HA, Li Y et al (1996) Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 10:745–752
Johansen KL, Mulligan K, Schambelan M (1999) Anabolic effect of nandrolone decanoate in patients receiving dialysis. JAMA 281:1275–1281
Strawford A, Barbieri T, Neese R et al (1999) Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 20:137–146
Berger JR, Pall L, Hall CD et al (1996) Oxandrolone in AIDS-wastingmyopathy. AIDS 10:1657–1662
Bonkovsky HL, Fiellin DA, Smith GS et al (1991) A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-terms effect on liver function. Am J Gastroenterol 86:1200–1208
Demling RH, Orgill DP (2000) The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 15:12–17
Romeyn M, Gunn N 3rd (2000) Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA 284:176
Yeh SS, DeGuzman B, Kramer T (2002) Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122:421–428
Krasner DL, Belcher AE (2000) Oxandrolone restores appetite. An increase in weight helps heal wounds. Am J Nurs 100:53
Demling R, De Santi L (1998) Closure of the ‘nonhealing wound’ corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage 44:58–62, 64, 66 passim
Langer CJ, Hoffman JP, Ottery FD (2001) Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 17(1 Suppl):S1–S20
Mwamburi DM, Gerrior J, Wilson IB et al (2004) Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis 38:895–902
Earthman CP, Reid PM, Harper IT et al (2002) Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enterai Nutr 26:357–365
Grinspoon S, Corcoran C, Parlman K et al (2000) Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133:348–355
Bhasin S, Storer TW, Javanbakht M et al (2000) Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283:763–770
Bhasin S, Storer TW, Asbel-Sethi N et al (1998) Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155–3162
Coodley GO, Coodley MK (1997) A trial of testosterone therapy for HIV-associated weight loss. AIDS 11:1347–1352
Bennell KL, Brukner PD, Malcolm SA (1996) Effect of altered reproductive function and lowered testosterone levels on bone density in male endurance athletes. Br J Sports Med 30:205–208
Morley JE, Perry HM 3rd, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152
Dolan S, Wilkie S, Aliabadi N et al (2004) Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Arch Intern Med 164:897–904
Schurgin S, Dolan S, Perlstein A et al (2004) Effects of testosterone administration on growth hormone pulse dynamics in human immunodeficiency virusinfected women. J Clin Endocrinol Metab 89:3290–3297
Svanberg E, Ohlsson C, Kimball SR, Lundholm K (2000) rhIGF-l/IGFBP-3 complex, but not free rhIGF-1, supports muscle protein biosynthesis in rats during semistarvation. Eur J Clin Invest 30:438–446
Wang W, Iresjo BM, Karlsson L, Svanberg E (2000) Provision of rhIGF-l/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model. Clin Nutr 19:127–132
Tai VW, Schambelan M, Algren H et al (2002) Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 35:1258–1262
Lo JC, Mulligan K, Noor MA et al (2001) The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86:3480–3487
Mulligan K, Tai VW, Schambelan M (1999) Use of growth hormone and other anabolic agents in AIDS wasting. JPEN J Parenter Enterai Nutr 23:S202–S209
Mulligan K, Tai VW, Schambelan M (1998) Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting—a clinical research center study. J Clin Endocrinol Metab 83:1542–1547
Schambelan M, Mulligan K, Grunfeld C et al (1996) Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 125:873–882
Cominelli S, Raguso CA, Karsegard L et al (2002) Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: a national study. Nutrition 18:583–586
Crown AL, Cottle K, Lightman SL et al (2002) What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 56:723–733
Roubenoff R (2000) Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am J Manag Care 6:1003–1016
Biolo G, Iscra F, Bosutti A et al (2000) Growth hormone decreases muscle glutamine production and stimulates protein synthesis in hypercatabolic patients. Am J Physiol Endocrinol Metab 279:E323–E332
Mynarcik DC, Frost RA, Lang CH et al (1999) Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration. J Acquir Immune Defic Syndr 22:49–55
Windisch PA, Papatheofanis FJ, Matuszewski KA (1998) Recombinant human growth hormone for AIDS-associated wasting. Ann Pharmacother 32:437–445
Ellis KJ, Lee PD, Pivarnik JM et al (1996) Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J Clin Endocrinol Metab 81:3033–3038
Von Roenn JH, Knopf K (1996) Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology (Huntingt) 10:1049–1056; discussion 1062–1064, 1067–1068
Papadakis MA, Grady D, Black D et al (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124:708–716
Kaiser FE, Silver AJ, Morley JE (1991) The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 39:235–240
Waters D, Danska J, Hardy K et al (1996) Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDSassociated wasting. Ann Intern Med 125:865–872
Brocker P, Vellas B, Albarede JL, Poynard T(1994) A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing 23:303–306
Boelens PG, Fonk JC, Houdijk AP et al (2004) Primary immune response to keyhole limpet haemocyanin following trauma in relation to low plasma glutamine. Clin Exp Immunol 136:356–364
Sahni M, Guenther HL, Fleisch H et al (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004–2011
Lai YN, Yeh SL, Lin MT et al (2004) Glutamine supplementation enhances mucosal immunity in rats with Gut-Derived sepsis. Nutrition 20:286–291
Akisu M, Baka M, Huseyinov A, Kultursay N (2003) The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis. Ann Nutr Metab 47:262–266
Rathmacher JA, Nissen S, Panton L et al (2004) Supplementation with a combination of betahydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN J Parenter Enterai Nutr 28:65–75
May PE, Barber A, D’Olimpio JT et al (2002) Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxybeta-methylbutyrate, arginine, and glutamine. Am J Surg 183:471–479
Clark RH, Feleke G, Din M et al (2000) Nutritional treatment for acquired immunodeficiency virusassociated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enterai Nutr 24:133–139
von Meyenfeldt MF (1999) Nutritional support during treatment of biliopancreatic malignancy. Ann Oncol 10(Suppl 4):273–277
Vazquez P, Gomez de Segura IA, Cos A et al (1996) Response of the intestinal mucosa to different enterai diets in situations of surgical stress and malnutrition. Nutr Hosp 11:321–327
Kinscherf R, Hack V, Fischbach T et al (1996) Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine. J Mol Med 74:393–400
Austgen TR, Chen MK, Dudrick PS et al (1992) Cytokine regulation of intestinal glutamine utilization. Am J Surg 163:174–179, discussion 179–180
Smith QR (1991) The blood-brain barrier and the regulation of amino acid uptake and availability to brain. Adv Exp Med Biol 291:55–71
Tayek JA, Bistrian BR, Hehir DJ et al (1986) Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer 58:147–157
Grunfeld C, Feingold KR (1991) The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3:143–158
Grunfeld C, Kotler DP (1992) Wasting in the acquired immunodeficiency syndrome. Semin Liver Dis 12:175–187
Doherty GM, Jensen JC, Alexander HR et al (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192–198
Landman D, Sarai A, Sathe SS (1994) Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis 18:97–99
Goldberg RM, Loprinzi CL, Mailliard JA et al (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13:2856–2859
Kruse A, Rieneck K, Kappel M et al (1995) Pentoxifylline therapy in HIV seropositive subjects with elevated TNF. Immunopharmacology 31:85–91
Sathe SS, Tsigler D, Sarai A, umar P (1995) Pentoxifylline impairs macrophage defense against Mycobacterium avium complex. J Infect Dis 172:863–866
Sathe SS, Sarai A, Tsigler D, Nedunchezian D (1994) Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. J Infect Dis 170:484–487
Greig NH, Giordano T, Zhu X et al (2004) Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp (Wars) 64:1–9
Kedar I, Mermershtain W, Ivgi H (2004) Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 110:260–265
Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V et al (1996) Effects of thalidomide on HIVassociated wasting syndrome: a randomized, double, blind, placebo-controlled clinical trial. AIDS 10:1501–1507
Zhou S, Kestell P, Tingle MD, Paxton JW (2002) Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging 19:85–100
Khan ZH, Simpson EJ, Cole AT et al (2003) Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 17:677–682
Sauer LA, Dauchy RT, Blask DE (2000) Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res 60:5289–5295
Meydani SN, Endres S, Woods MM et al (1991) Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 121:547–555
Dinarello CA, Endres S, Meydani SN et al (1990) Interleukin-1, anorexia, and dietary fatty acids. Ann N Y Acad Sci 587:332–338
Endres S, Ghorbani R, Kelley VE et al (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271
Tisdale MJ, Dhesi JK (1990) Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res 50:5022–5026
Costelli P, Llovera M, Lopez-Soriano J et al (1995) Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Lett 97:25–32
Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486
Jatoi A, Rowland K, Loprinzi CL et al (2004) An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22:2469–2476
Roederer M, Staal FJ, Raju PA et al (1990) Cytokinestimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc_Natl Acad Sci USA 87:4884–4888
Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662
Loprinzi CL, Kuross SA, O’Fallon JR et al (1994) Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121–1125
Loprinzi CL, Goldberg RM, Su JQ et al (1994) Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1126–1129
Lissoni P, Paolorossi F, Tancini G et al (1996) Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A:1340–1343
Maughan R (1995) Creatine supplementation and exercise performance. International journal of sport nutrition 5:94–101
Engelhardt M, Neumann G, Berbalk A, Reuter I (1998) Creatine supplementation in endurance sports. Med Sci Sports Exerc 30:1123–1129
Greenhaff PL, Casey A, Short AH et al (1993) Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man. Clin Sci (Lond) 84:565–571
Birch R, Noble D, Greenhaff PL (1994) The influence of dietary creatine supplementation on performance during repeated bouts of maximal isokinetic cycling in man. Eur J Appl Physiol Occup Physiol 69:268–276
Greenhaff PL (1995) Creatine and its application as an ergogenic aid. Int J Sport Nutr 5:S100–S110
Terjung RL, Clarkson P, Eichner ER et al (2000) American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 32:706–717
Williams MH, Branch JD (1998) Creatine supplementation and exercise performance: an update. J Am Coll Nutr 17:216–234
Redondo DR, Dowling EA, Graham BL et al (1996) The effect of oral creatine monohydrate supplementation on running velocity. Int J Sport Nutr 6:213–221
Hyltander A, Daneryd P, Sandstrom R et al (2000) Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer 36:330–334
Roe S, Cooper AL, Morris ID, Rothwell NJ (1996) Mechanisms of cachexia induced by T-cell leukemia in the rat. Metabolism 45:645–651
Szabo K (1979) Clinical experiences with beta adrenergic blocking therapy on burned patients. Scand J Plast Reconstr Surg 13:211–215
Lamont LS, Brown T, Riebe D, Caldwell M (2000) The major components of human energy balance during chronic beta-adrenergic blockade. J Cardiopulm Rehabil 20:247–250
Reichel K, Rehfeldt C, Weikard R et al (1993) Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats. Arch Tierernahr 45:211–225
Arbabi S, Ahrns KS, Wahl WL et al (2004) Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma 56:265–269; discussion 269–271
Kawakami M, He J, Sakamoto T, Okada Y (2001) Catecholamines play a role in the production of interleukin-6 and interleukin-lalpha in unburned skin after burn injury in mice. Crit Care Med 29:796–801
Hryniewicz K, Androne AS, Hudaihed A, Katz SD (2003) Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 9:464–468
Gambardella A, Tortoriello R, Pesce L et al (1999) Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients. Metabolism 48:291–297
Hussey HJ, Tisdale MJ (2000) Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 87:95–100
Cahlin C, Gelin J, Delbro D et al (2000) Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60:1742–1743
Gelin J, Moldawer LL, Lonnroth C et al (1991) Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 51:415–421
Gelin J, Andersson C, Lundholm K (1991) Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51:880–885
Wang W, Lonnroth C, Svanberg E, Lundholm K (2001) Cytokine and cyclooxygenase-2 protein in brain areas of tumor-bearing mice with prostanoidrelated anorexia. Cancer Res 61:4707–4715
Cahlin C, Korner A, Axelsson H et al (2000) Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferongamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60:5488–5493
Lundholm K, Gelin J, Hyltander A et al (1994) Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602–5606
Adigun AQ, Ajayi AA (2001) The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail 3:359–363
Anker SD, Negassa A, Coats AJ et al (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361:1077–1083
Asakawa A, Inui A, Kaga T et al (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345
Hao S, Avraham Y, Mechoulam R, Berry EM (2000) Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392:147–156
Kawamura I, Yamamoto N, Sakai F et al (1999) Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res 19:341–348
Kawamura I, Lacey E, Yamamoto N et al (1999) Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinomain mice. Anticancer Res 19:4105–4111
Kawamura I, Yamamoto N, Sakai F et al (1999) Effect of lipoprotein lipase activators bezafibrate and NO1886, on B16 melanoma-induced cachexia in mice. Anticancer Res 19:4099–4103
Kawamura I, Lacey E, Inami M et al (1999) Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. Anticancer Res 19:4091–4097
Agteresch HJ, Dagnelie PC, van der Gaast A et al (2000) Randomized clinical trial of adenosine 5’-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321–328
Agteresch HJ, Burgers SA, van der Gaast A et al (2003) Randomized clinical trial of adenosine 5’-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 14:639–644
Ishiko O, Yasui T, Hirai K et al (1999) Lipolytic activity of anemia-inducing substance from tumor-bearing rabbits. Nutr Cancer 33:201–205
Ishiko O, Hirai K, Nishimura S et al (1999) Elimination of anemia-inducing substance by cyclic plasma perfusion of tumor-bearing rabbits. Clin Cancer Res 5:2660–2665
Ishiko O, Sumi T, Yoshida H et al (2001) Angiogenesis in the adipose tissue of tumor-bearing rabbits treated by cyclic plasma perfusion. Int J Oncol 19:785–790
Ishiko O, Yoshida H, Sumi T et al (2001) Expression of skeletal muscle cells apoptosis regulatory proteins in plasma-perfused VX2 carcinoma-bearing rabbits. Anticancer Res 21:2363–2368
Josephs MD, Solorzano CC, Taylor M et al (2000) Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-Ira. Am J Physiol Regul Integr Comp Physiol 278:R824–R830
Carbo N, Lopez-Soriano J, Costelli P et al (2000) Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 83:526–531
Figueras M, Busquets S, Carbo N et al (2004) Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 569:201–206
Schwartz SA, Hernandez A, Mark Evers B (1999) The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg Oncol 8:143–153
Kawamura I, Morishita R, Tsujimoto S et al (2001) Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8:905–912
Kawamura I, Morishita R, Tomita N et al (1999) Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6:91–97
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Italia
About this chapter
Cite this chapter
Yeh, SS., Schuster, M.W. (2006). Treatment of Cachexia in the Elderly. In: Mantovani, G., et al. Cachexia and Wasting: A Modern Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-0552-5_68
Download citation
DOI: https://doi.org/10.1007/978-88-470-0552-5_68
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0471-9
Online ISBN: 978-88-470-0552-5
eBook Packages: MedicineMedicine (R0)